Implant Sciences Corporation (OTCQB:IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that the Company has received an order for 25 QS-B220 explosives trace detection systems from a major airport in France. The systems, which will be used to fulfill the recent European security regulations requirement for screening passengers and checked bags, are expected to be delivered in the Company's fourth fiscal quarter, ending June 30, 2015.
"Our QS-B220 was selected for its superior performance in the airport operating environment. After conducting a long operational performance evaluation at the airport, the QS-B220's performance was demonstrated to be far superior to the competition. This, along with the fact that the QS-B220 is the only non-rad ETD to have both the original STAC (France's ETD approval) as well as the ECAC (European Civil Aviation Conference) qualification, drove the purchasing decision," stated Dr. Darryl Jones, Implant Sciences' Vice President of Global Sales and Marketing. "We are very proud that Implant Sciences has won a number of procurements in head-to-head competition with our major competitors in Europe. We are committed to providing the best technology and services to meet our clients' needs in this demanding market."
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as illicit drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
Source: Implant Sciences Corporation
Date: Apr 29, 2015